Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates
Niva Bupa Health Insurance recently announced a major financial milestone for the fourth quarter of the fiscal year. The company reported a significant 67 percent surge in its net profit. Specifically, this figure reached Rs 345 crore during the March quarter. This growth highlights the insurer\'s robust position in India\'s expanding health insurance market. The total income during this period increased to Rs 2,078 crore. This represents a substantial rise from Rs 1,565 crore in the year-ago period.
Furthermore, the gross written premium grew to Rs 2,880 crore. This momentum is supported by the insurer\'s expanding footprint in the retail health segment. The company reported a claim settlement ratio of 94.4 percent for FY26. This metric shows a 205 basis point improvement over the prior fiscal year. Consequently, it reflects a strong focus on enhancing the customer claims experience. However, the solvency ratio declined to 2.49 from 3.03. Even with this decline, the ratio remains well above the regulatory requirement of 1.5.
In addition to financial gains, the board approved the elevation of Ankur Kharbanda to Deputy CEO. This move became effective on May 8, 2026. Moreover, the company’s retail health market share improved to 10.1 percent. CEO Krishnan Ramachandran emphasized that these gains reflect growing customer trust. Additionally, the company aims to continue delivering superior insurance experiences. These results indicate a positive trend for both the company and its policyholders across India.
Q1: What was the claim settlement ratio for Niva Bupa in FY26?
Niva Bupa achieved a claim settlement ratio of 94.4 percent for the 2025-26 fiscal year. This figure represents an improvement of 205 basis points over the previous year.
Q2: Who has been appointed as the new Deputy CEO of the company?
The board approved the elevation of Ankur Kharbanda to the position of Executive Director and Deputy Chief Executive Officer, effective May 8, 2026.
Q3: How much did the net profit grow in the fourth quarter?
The net profit jumped by 67 percent to reach Rs 345 crore in the fourth quarter, compared to Rs 206 crore in the same period last year.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
Niva Bupa Health Insurance reports a 67% profit surge to Rs 345 crore and a 94.4% claim settlement ratio for FY26, signaling strong retail growth....
last month
A recent study reveals that PYCR1 drives osteosarcoma proliferation by activating the PI3K/Akt signaling pathway and inhibiting ferroptosis. These findings highlight PYCR1 as a critical metabolic regulator and a potential therapeutic target for treating drug-resistant and metastatic bone cancer.
Today
A large-scale retrospective study reveals a sharp rise in gestational and type 2 diabetes alongside severe maternal morbidity between 2016 and 2022. While gestational diabetes is most prevalent, type 1 diabetes poses the highest risk for maternal complications, necessitating multidisciplinary care.
Today
AI is transforming pediatric radiology by enhancing diagnostic accuracy in neuroimaging, cardiovascular care, and oncology. This primer explores the current landscape of pediatric-specific AI tools, highlighting benefits like automated bone age assessment and the critical need for child-centered validation.
Today
Researchers developed a pose-aware deep perceptual metric using contrastive learning to improve 2D/3D registration of knee joints. This AI-driven approach enhances capture range, robustness to noise, and accuracy in joint kinematics analysis for orthopedic procedures.
Today
A target trial emulation study within the Veterans Health Administration shows that starting CGM therapy is associated with a 10% to 16% reduction in all-cause mortality for older-onset type 1 diabetes patients, particularly those over 65 or not using insulin pumps.
Today